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human OSCC pathogenesis by mediating OSCC cell 
spreading, migration, and invasion
Pachiyappan Kamarajan1, Angeles Garcia-Pardo2, Nisha J D'Silva1 and Yvonne L Kapila*1
Abstract
Background: The alternatively spliced V region or type III connecting segment III (IIICS) of fibronectin is important in 
early development, wound healing, and tumorigenesis, however, its role in oral cancer has not been fully investigated. 
Thus, we investigated the role of CS-1, a key site within the CSIII region of fibronectin, in human oral squamous cell 
carcinoma (OSCC).
Methods: To determine the expression of CS-1 in human normal and oral SCC tissue specimens immunohistochemical 
analyses were performed. The expression of CS1 was then associated with clinicopathological factors. To investigate 
the role of CS-1 in regulating OSCC cell spreading, migration and invasion, OSCC cells were assayed for spreading and 
migration in the presence of a CS-1 peptide or a CS-1 blocking peptide, and for invasion using Matrigel supplemented 
with these peptides. In addition, integrin α4siRNA or a focal adhesion kinase (FAK) anti-sense oligonucleotide was 
transfected into OSCC cells to examine the mechanistic role of integrin α4 or FAK in CS1-mediated cell spreading and 
migration, respectively.
Results: CS-1 expression levels were significantly higher in OSCC tissues compared to normal tissues (p < 0.05). Also, 
although, high levels of CS-1 expression were present in all OSCC tissue samples, low-grade tumors stained more 
intensely than high grade tumors. OSCC cell lines also expressed higher levels of CS-1 protein compared to normal 
human primary oral keratinocytes. There was no significant difference in total fibronectin expression between normal 
and OSCC tissues and cells. Inclusion of CS-1 in the in vitro assays enhanced OSCC cell spreading, migration and 
invasion, whereas the CS1 blocking peptide inhibited these processes. Suppression of integrin α4 significantly inhibited 
the CS1-mediated cell spreading. Furthermore, this migration was mediated by focal adhesion kinase (FAK), since FAK 
suppression significantly blocked the CS1-induced cell migration.
Conclusion: These data indicate that the CS-1 site of fibronectin is involved in oral cancer pathogenesis and in 
regulating OSCC cell spreading, migration and invasion.
Background
Oral squamous cell carcinoma is the most common type
of oral cancer accounting for almost 90% of all oral malig-
nancies, and it continues to have a poor 5 year survival
rate [1]. Improved survival can only result from scientific
advances and a better understanding of risk factors asso-
ciated with the disease. Identification of specific mole-
cules associated with malignant transformation has led to
the identification of an increasing number of molecular
markers that are related to tumor stage and grading and
may have a prognostic value for the disease [2]. Signifi-
cant knowledge has also been gained about key molecules
that regulate the cell cycle, apoptosis, immunologic
tumor defense, and extracellular matrix interactions and
breakdown in oral cancer [3-6].
One such extracellular matrix molecule important in
tumorigenesis and in cell differentiation, proliferation,
migration, and survival is fibronectin [7]. Fibronectin is a
ubiquitous protein present in tissues and body fluids,
including plasma that engages in these cellular functions
and provides architectural scaffolding for cells and tis-
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Page 2 of 8sues. The fibronectin gene contains three separate exons
that undergo alternative splicing, to yield the ED-A, ED-B
and IIICS/V regions (Figure 1A) [8]. The presence of
additional acceptor and donor splice signals within the
IIICS region allows generation of multiple IIICS polypep-
tide variants, namely, three in rat fibronectin [8,9] and
five in human fibronectin [10,11], thus increasing
fibronectin diversity. One subset of these molecular vari-
ants expresses a 25 amino acid sequence within the IIICS
region termed CS1 isoform or CS1 site, [12,13] which is a
counter-receptor for the α4β1 (VLA4) integrin [14,15].
The CS1 site mostly mediates adhesion of lymphoid cells
and some tumor cells [13,14]. Another cell adhesive site is
located within the carboxyl-terminal 31 residues of IIICS
and it is referred to as CS5. The adhesive activity of CS5 is
much weaker than that of CS1 [13]. Thus, in addition to
the classical α5β1 fibronectin receptor, which recognizes
the Arg-Gly-Asp sequence within fibronectin, the CS1
region functions as an alternative cell attachment site for
certain cell types [16,17].
The alternatively spliced segments of fibronectin are
thought to play a role in embryonic development, wound-
ing healing, and tumorigenesis [18-20]. However, to our
knowledge a comparative study of the role of the CS1 site
of fibronectin in oral squamous cell carcinomas (OSCC)
of various grades combined with in vitro analyses of its
function have not yet been conducted. A limited study of
10 OSCC tissue specimens detected CS-1 expression by
RT-PCR in these tissues, but significant correlations did
not emerge likely due to the limited sample size [21]. In
the present investigation, we performed a comparative
analysis of CS1 expression patterns on OSCCs with dif-
ferent tumor grades. In vitro examination of the role of
CS1 in OSCC cell spreading, migration, and invasion was
Figure 1 CS1 expression is correlated with OSCC in tissues and cells. (A) Schematic representation of the domain structure of human fibronectin 
and the possible protein products arising from alternative splicing of the IIICS region. (B) CS1 expression levels in normal and SCC tissues are illustrated. 
CS1 staining intensity low and high are shown in low (a, e, b and f) and high magnification (c, g, d and h) images (Arrows, epithelium, arrowheads, 
connective tissue). (C) Immunoblot showing CS1 levels in normal kerotinocytes (K1, K2, two different patient isolates) and SCC cells (HSC-3, UM-SCC1, 
UM-SCC17B, UM-SCC14A and OSCC3) and fold change shows results from densitometric analysis of CS1 normalized to β-actin. Plasma fibronectin 
(plasma FN) served as positive control. (D) CS1 and fibronectin expression levels in normal and SCC tissues are illustrated (Arrows, epithelium; arrow-
heads, connective tissue). (E) Immunoblots showing the levels of CS1 and fibronectin in kerotinocytes and SCC cells.
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Page 3 of 8also performed. We demonstrate that the expression of
the alternatively spliced CS1 site is associated with OSCC
tumorigenesis as it is highly expressed in low grade
tumors. These data therefore indicate that the CS-1
fibronectin site may play an important role in the pathol-
ogy of OSCC.
Methods
Cell lines and peptides
The highly invasive human oral SCC cell line HSC-3
(tongue) [22] was kindly provided by Randy Kramer (Uni-
versity of California, San Francisco). The human oral
SCC cell lines, UM-SCC-1 (floor of mouth), UM-SCC-
17B (larynx), and UM-SCC-14A (floor of mouth) were
gifts from Tom Carey (University of Michigan, Ann
Arbor). The poorly differentiated aggressive tongue SCC
cell line OSCC-3 was gift from Mark Lingen (University
of Chicago, Chicago). Primary human oral keratinocytes
were derived from normal gingival tissues discarded fol-
lowing periodontal surgical procedures, as approved by
the University of Michigan IRB. OSCC cells were main-
tained in a 5% CO 2 atmosphere at 37°C in DMEM
(Gibco) supplemented with 10% fetal bovine serum, 1%
penicillin, and 1% streptomycin. CS-1 peptide
(EILDVPST) (H-2094) and CS-1 blocking peptide (VLA4
inhibitor, Phenyllac-Leu-Asp-Phe-D-Pro-NH 2) (H3376)
were purchased from Bachem. CS1 blocking peptide
blocks the binding of the very late antigen (VLA4) integ-
rin to fibronectin. Control scrambled peptide, Scr1 (H-
Ser-Ile-Glu-Leu-Thr-Pro-Val-Ala-OH) or Scr2 (H-Ser-
Ile-Glu-Leu-Thr-Pro-Val-Asp-OH) was synthesized by
the Protein Structure Facility, University of Michigan.
Primary oral keratinocytes were maintained in Epilife
media.
Peptide conjugation to BSA
Synthetic peptides were chemically conjugated to BSA
using glutaraldehyde (GA) (Sigma) as the cross linker and
these were prepared by the Protein Structure facility, Uni-
versity of Michigan. Briefly, BSA (10 mg/ml) was dis-
solved in conjugation buffer and mixed with GA to a
concentration of 1.25%. After overnight incubation at
room temperature, unreacted GA was removed by gel fil-
tration on a G-25 sephadex column. The activated BSA (2
ml GA-BSA) was then added to peptides [(5 mg/ml; Scr,
CS1 and CS1 Blocking peptide (VLA4 inhibitor)] and
incubated at room temperature for 1 h and overnight at
4°C. Free peptides were removed by dialysis against 0.1 M
PBS overnight at 4°C. The concentration of final conju-
gates was estimated based on BSA concentration.
Tissues and Tissue Microarrays
Immunohistochemical analysis was performed to deter-
mine the expression of CS-1 in human normal and OSCC
tissue specimens (Tissue microarrays, OR601 Biomax.us
and HN241, Accumax) using the histostatin kit (95-6143,
Zymed lab) as per the manufacturer's instructions. In
addition, 5 representative tissue samples of OSCC and 5
normals were obtained from tissue core facility, Univer-
sity of Michigan and Accumax (HN241) for CS1 and
fibronectin expression. Briefly, after antigen retrieval by
microwave pretreatment (citrate buffer, 10 mM, pH 6.0),
slides were incubated with a CS1 primary antibody
(P1F11) [23] or fibronectin (clone 2Q604, Santa Cruz
Biotechnology) overnight at 4°C. For negative controls,
slides were incubated with mouse IgG as the primary
antibody. After diaminobenzidine chromogen (DAB)
reaction, slides were counterstained with routine hema-
toxylin. Immunohistochemical staining for CS-1 grading
was evaluated and scored by a pathologist in a blinded
manner.
Immunoblot analysis
For immunoblot analysis, cells were lysed in RIPA lysis
buffer containing protease inhibitors (50 mM Tris/HCl,
pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EGTA, 1 mM PMSF, 1% protease
inhibitor cocktail (P8340, Sigma), 1 mM Na 3VO 4, and 1
mM NaF) on ice for 30 min. Proteins were resolved by
SDS-PAGE, transferred to Immobilon-P membranes
(Millipore) and blots were probed with antibodies to CS-
1 fibronectin (clone P1F11, Chemicon), fibronectin (H-
300, Santa Cruz Biotechnology), FAK (clone 2A7, Upstate
Biotech) or β-actin (clone C-11, Santa Cruz Biotechnol-
ogy). The antigen and antibody complexes were devel-
oped with the ECL-Plus detection system (Pierce). All
other reagents were from Sigma.
Cell spreading assay
Briefly, 1 × 10 4 cells were re-suspended in 100 μl serum
free DMEM containing the scrambled peptide, CS1 pep-
tide or CS1 blocking peptide. Cells were then plated in a
96 well plate, and incubated at 37°C in a humidified 5%
CO2 incubator for 3 h. The assay measuring cell spread-
ing on immobilized peptides was carried out as described
[12,13]. Briefly, BSA conjugated peptides (Scr-BSA, CS1-
BSA and CS1 blocking-BSA (VLA4 inhibitor) were
diluted to various concentrations in PBS and 100 μl ali-
quots were added to 96 well plates. Peptides were allowed
to adsorb overnight at 37°C, and then nonspecific binding
sites were blocked with 10 mg/ml BSA in PBS for 1 h.
Cells were plated at 1 × 10 4 cells/well in 100 μl of serum
free DMEM and then incubated at 37°C in a humidified
5% CO2 incubator for 3 h. In another experiment, cells
were transfected with integrin α4 siRNA (100 pM,
Ambion) for 36 h and then plated in 96 well plates. Cell
spreading was assessed under the microscope and by
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lated using NIS-Elements BR-3.0 imaging software.
Migration assay
Migration assays were performed as previously described
[24]. Cells grown overnight were wounded uniformly
using plastic pipette tips, and cultured for 16 h in the
presence of scrambled CS1 peptide, CS1 peptide or CS1
blocking peptide. In another experiment, cells were trans-
fected with control oligonucleotides or FAK anti-sense
oligonucleotides (Oligos Etc) [25] and incubated with
CS1 peptide for 16 h. Standard photographs were taken
of the wounded areas using NIS-Elements BR-3.0 imag-
ing software. The cell migration distance was calculated
by subtracting the distance at the lesion edge at 16 h from
the distance measured at 0 h.
Matrigel invasion assay
Briefly, transwell inserts with 8 μM pores (Becton Dickin-
son) were coated 50 μl matrigel (BD Matrigel?, BD Biosci-
ences). Cells at 1 × 10 6 were seeded in the upper
chambers with 100 μl of serum free medium. Serum free
medium (650 μl) supplemented with scrambled peptide
or various concentrations of CS1 peptide were placed in
the lower chambers and incubated at 37°C for 24 h. Cells
that invaded the matrigel-coated membrane and emerged
on the underside surface of the membrane were labeled
with Calcein AM fluorescent dye (BD Biosciences) as per
the manufacturer's instructions. Fluorescence intensity
was read at 485/520 in a fluorescence spectrophotometer
(SPECTRA max M2, Molecular Devices) and reported as
fold change in invasion relative to a media control.
Statistical analysis
In general, values are expressed as means ± SD. Inter-
group differences were determined by two-way analysis
of variance (ANOVA) and Scheffe's multiple-comparison
test. Statistical significance was defined as *, # p ≤ 0.05.
For tissue microarray analysis a chi-square test was
employed. All experiments were repeated in triplicate.
Results
CS1 expression is correlated with OSCC
To examine CS1 expression in OSCCs, immunohis-
tochemical analyses were performed using tissue
microarrays of OSCCs. A total of 80 samples, 63 malig-
nant and 17 normal tissues, from 52 males and 28 female
patients were analyzed. The age range of the patients was
21 to 80 years. Tumors of grade I to IV from the tongue,
cheek, gingiva, lip and oral mucosa were analyzed and
compared to normal tissue from similar anatomical loca-
tions.
Examples of tissue microarray staining for CS-1 protein
expression in OSCCs and normal tissue samples that
exhibited high and low level staining are represented (Fig-
ure 1B). Normal epithelium expressed nuclear and cyto-
plasmic staining, whereas cancer cells expressed
cytoplasmic staining. The staining intensity was assessed
as low or high. CS1 expression levels were significantly
higher in OSCC tissues compared to normal tissues
(Table 1, p < 0.03). Also, although, all levels of CS-1
expression were present in the various OSCC tissue sam-
ples (Table 1), low grade tumors (Group I) stained at a
higher level of intensity compared to that of high grade
tumors (Group II) (p < 0.01). Furthermore, CS1 staining
Table 1: Correlation of CS1 containing fibronectin expression and clinicopathological variables in normal and oral SCC 
tissues
No. of tissue specimens CS1 staining intensity [No. of tissue specimens(%)] P value
Low High
Normal 17 9 (53) 8 (47)
Tumor 63 15 (24) 48 (76) Normal vs Tumor 0.03*
Tumor grade vs CS1 staining
Group-I (I, I-II and II)a 49 8 (16) 41 (84)
Group-II (II-III, III and IV) a 14 7(50) 7 (50) Group I vs Group II 0.01*
Organ vs CS1 staining
Normal 8 4 (50) 4 (50)
Tongue
Tumor 26 7 (24) 19 (76) Normal vs Tumor 0.05*
Tongue
aParenthetical data under tumor grade vs CS1 staining denote original tumor grade provided in tumor microarray. These grades were pooled 
into groups for purposes of statistical analysis.
Statistical analysis: Chi-square test; *significant difference p ≤ 0.05
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from OSCCs compared to the normal tissues (p < 0.05).
Importantly, there were significant differences in CS1,
but not in total fibronectin expression between normal
and SCC tissues (Figure 1D). Comparisons between age
or gender and CS1 staining did not show any significant
correlations. Other organ specific comparisons were not
possible because of low sample size.
To further validate the importance of CS1 in OSCC,
CS1 expression was examined in several human OSCC
cell lines and normal primary human oral keratinocytes.
Similar to the tissue microarray staining pattern, OSCC
cells expressed higher levels of CS1 compared to the nor-
mal primary keratinocytes (Figure 1C). There was no sig-
nificant difference between OSCC cells and primary
keratinocytes in fibronectin levels (Figure 1E).
CS1 mediates OSCC cell spreading
To determine the contribution of the IIICS (V) region of
fibronectin, especially of the CS1 site to attachment and
spreading of human OSCC cells, we measured the effect
of a peptide containing the CS1 sequence on these pro-
cesses. CS1 promoted OSCC cell spreading in a dose-
dependent manner compared to a scrambled CS1 peptide
control or media control. Spreading was robust with 80
μg/ml of CS1 in both cell lines (Figure 2A and 2B top
panel). In contrast, the CS1 blocking peptide (VLA4
inhibitor) abrogated OSCC cell spreading. To further
confirm the ability of CS1 peptides to mediate spreading,
OSCC cells were plated onto surfaces coated with immo-
bilized peptides coupled with BSA. Under these condi-
tions, significant cell spreading was again observed in
CS1-BSA coated wells compared to those coated with
Scr-BSA, and CS1 blocking peptide-BSA (VLA4 inhibi-
tor) inhibited OSCC spreading (Figure 2C top panel).
Thus, CS1 promotes cell spreading in OSCC cells. The
percentage of OSCC cell spreading under these different
conditions was quantified and illustrated (Figure 2A, B
and 2C bottom panel). Since integrin α4 is a counter-
receptor for CS1 we examined the role of integrin α4 in
OSCC cell spreading. Suppression of integrin α4 with
siRNA significantly inhibited the CS1-mediated cell
spreading (Figure 2D).
CS1 promotes human OSCC cell migration and invasion
Next we investigated whether CS1 is involved in migra-
tion of OSCC cells using wound-healing assays. In the
presence of CS1, OSCC cells exhibited increased migra-
tion compared to controls (Figure 3A middle panel). In
contrast, the CS1 blocking peptide (VLA4 inhibitor)
abrogated OSCC cell migration compared to CS1 treated
samples and controls (Figure 3A bottom panel). A scram-
bled peptide for CS1 did not influence the migration
more than that of control cells incubated in media alone
(Figure 3A top panel). The percentage of OSCC cell
migration under these different conditions was quantified
and illustrated (Figure 3B and 3C).
To assess downstream signaling in CS1 induced migra-
tion, we investigated the role of FAK in OSCC cells. In
CS1 treated cells, FAK phosphorylation at Tyr-925
increased (Figure 3D top left panel). Furthermore, this
migration is mediated by focal adhesion kinase (FAK),
since FAK suppression significantly blocked the CS1-
induced cell migration (Figure 3D bottom panel). The
percentage of OSCC cell migration under these different
conditions was quantified and illustrated (Figure 3E).
To explore the ability of CS1 to modulate cell invasion
by OSCC cells, matrigel invasion assays was performed.
These assays showed that CS1 significantly increased the
invasiveness of OSCC cells in a dose-dependent manner,
unlike the media or scrambled CS1 peptide controls (Fig-
ure 3F). Altogether our results show that CS1 promotes
OSCC cell migration and invasion.
Discussion
The present study was performed to evaluate the signifi-
cance of the CS1 site of fibronectin in OSCC pathogene-
sis. CS1 has been previously associated with increased
cell adhesion in human lymphoma, rhabdomyosarcoma,
and mouse melanoma cells [26]. Although the physiologi-
cal significance of the molecular diversity of fibronectin
at its three variable regions (ED-A, ED-B and IIICS)
remains poorly understood, several lines of evidence indi-
cate that splicing variations at the IIICS region modulate
the adhesive and migrating properties of cells [13,16,27].
However, none of the studies reported to date have
explored the role of the CS1 site in OSCC pathogenesis.
Our data showed that alternative splicing of the IIICS
region of fibronectin was deregulated in oral cancer tis-
sues with a significant increase in the CS1 isoform. The
importance of CS1 in tumorigenesis emerged from the
tissue microarray data showcasing a statistically signifi-
cant opposite relationship of staining intensity for CS1
between OSCC and normal oral tissues. There was no
significant difference in total fibronectin expression
between normal and OSCC tissues. The higher level of
CS1 staining exhibited by most of the OSCC tissues in
contrast to the lower level of staining in the normal tis-
sues and its cytoplasmic preferential localization sup-
ports a role for CS1 in OSCC pathogenesis. Also,
although, all levels of CS-1 expression were present in the
various OSCC tissue samples, low-grade tumors stained
at a higher level of intensity compared to that of high
grade tumors, suggesting that CS1 is involved in the early
stages of tumorigenesis. Higher CS1 protein expression
but not total fibronectin levels in OSCC cell lines com-
pared to primary keratinocytes further validated the
importance of CS1 in this process. Other investigators
Kamarajan et al. BMC Cancer 2010, 10:330
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mRNA containing the CS1 sequence was significantly
increased in both fetal and cancerous liver tissue,
although it was not altered in non-malignant tissues
derived from chronic hepatitis and cirrhosis patients [28].
Furthermore, the CS1 peptide increases cell adhesion of
human epithelial carcinoma (A431) [29] and leukemic
monocyte lymphoma cells (U937), and a CS1 blocking
peptide (VLA4 inhibitor) or α4β1 function-blocking
monoclonal antibodies inhibited cell adhesion and inva-
sion by U937 and lung tumor cells [17,30]. In addition,
CS1 isoforms are present on the synovial endothelium of
rheumatoid arthritis patients, and adhesion of T lympho-
blastoid cells to this endothelium could be abrogated by
an anti-α4 integrin antibody or by a synthetic CS1 pep-
tide (VLA4 inhibitor) [31]. Further, our findings suggest
that CS1-mediated cell adhesion in OSCC cells was regu-
lated by integrin α4. Indeed, we have previously shown
these OSCC cells express the VLA4 receptor, which
therefore can enable interactions via CS1 [25,32].
Cell migration is essential for invasion and metastasis
of cancer cells [33]. It involves the assembly and disas-
sembly of focal adhesion complexes. These integrin-
linked complexes are the primary sites of adhesion
between cells and the surrounding extracellular matrix
[34]. FAK plays a central role in the turnover of these
adhesion sites [35]. FAK controls the dynamic process of
integrin-linked adhesions and is an important regulator
of cell migration. Increased FAK expression and activity
are frequently correlated with malignant or metastatic
disease and poor patient prognosis [36-39]. Previously we
demonstrated that an altered fibronectin matrix induces
anoikis of human squamous cell carcinoma cells by sup-
pressing phosphorylation of FAK and ERK [25]. Our
present results, which show that FAK suppression blocks
CS1-mediated OSCC cell migration, further supports the
Figure 2 CS1 fibronectin enhances spreading of SCC cells (HSC-3 and UM-SCC14A). (A and B top panel) cells were incubated in serum free media 
containing scramble peptide (Scr1, and Scr2), CS1 peptide or CS1 blocking peptide as indicated for 3 h and photographed (X200). (C top panel) Cells 
were cultured in 96 plates coated with Scr-BSA, CS1-BSA or CS1 blocking-BSA (VLA4 inhibitor) as indicated for 3 h and photographed (X200). (A, B and 
C bottom panel) The percentage of SCC cell spreading under these different conditions was quantified and illustrated. D. Integrin α4 suppression in-
hibits CS1-mediated cell spreading. Percentage of spreading after transfected with integrin α4 siRNA or the control siRNA and plated in a CS1-BSA (40 
μg/ml) or Scr-BSA (40 μg/ml) coated wells. Inset, Immunoblot showing integrin α4 expression in cells transfected with control or integrin α4 siRNA 
(100 pM). Data represent mean ± SD from three independent experiments *, # p < 0.05.
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Page 7 of 8concept that CS1 promotes OSCC cell adhesion and
migration in a FAK rich environment, and this may con-
tribute to tumorigenesis.
Conclusions
In summary, our data suggest that the increased expres-
sion of CS1 by OSCC cells may, in the early stages of
pathogenesis, facilitate the local migration and invasion
of these cells into the surrounding extracellular matrix to
become locally aggressive.
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Figure 3 CS1 fibronectin enhanced SCC cell (HSC-3 and UM-SCC14A) migration and invasion in wound healing assays. (A) Repair of the 
wound by cell migration in the presence of a scrambled peptide (Scr1 and Scr2), CS1 peptide or CS1 blocking peptide was compared to that in control 
cells incubated in media alone at 0 and 16 h (Control, 0 and 16 h) and photographed (X200). (B and C) The total migrating distance of cells from edges 
of the wounds were measured after 16 h. (D) (Top left) Immunoblot showing the phospho FAK and FAK levels in controls or CS1 treated HSC-3 cells. 
(Top right) Immunoblot showing the FAK levels in HSC-3 cells after transfection with FAK antisense oligonucleotides (FAK-As) or scrambled sequence 
for 36 h (1.0 μg). (Middle and bottom panel), Cells were left untransfected or transfected with FAK antisense olgonucleotides (FAK-As) for 36 h. Repair 
of wound by cell migration with CS1 peptide or scramble peptide was photographed (X200). (E) The total migrating distance of cells from edges of 
the wounds (D middle and bottom panel) were measured after 16 h. (F) CS1 fibronectin mediates HSC-3 cell invasion. Fold change of cells invading 
through matrigel-coated pored membrane in control and CS1 treated group. Data represent mean ± SD from three independent experiments *, # p 
< 0.05.
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